Medetomidine: Emerging Adulterant with Significant Clinical Implications_Online

This presentation will explore the pharmacologic mechanism of the drug, its acute toxicity, and the complex withdrawal syndrome that has resulted in approximately 90% of patients requiring ICU admission. The session will also cover treatment recommendations that have been developed through direct patient care and collaboration with academic colleagues at various sites which have recently been published in the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report (MMWR).

Target Audience

This course is designed for health care professionals including Physicians, Physician Assistants, Nurse Practitioners, Pharmacists and Nurses.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the demographics and public health response related to medetomidine use.
  • Analyze the structure and pharmacology of medetomidine.
  • Assess the acute toxicity of medetomidine and formulate appropriate management strategies.
  • Identify the withdrawal syndrome associated with medetomidine and develop effective management strategies.
  • Explain the impact of medetomidine use on patient disposition and long-term consequences.

Disclaimer Statement:

The information presented at this activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine.  Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

Course summary
Available credit: 
  • 1.00 AAPA Category I CME
    • 1.00 Opioid Education
  • 1.00 ACPE Pharmacy
    The UPMC Center for Continuing Education in the Health Sciences is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a Provider of continuing pharmacy education.
    • 1.00 Opioid Education
  • 1.00 AMA PRA Category 1 Credit™
    The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
    • 1.00 Opioid Education
  • 1.00 ANCC
    UPMC Provider Unit is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation
    • 1.00 Opioid Education
  • 1.00 Attendance
    • 1.00 Opioid Education
Course opens: 
05/23/2025
Course expires: 
05/23/2028
Part of: 
DEA MATE ACT FOR PRESCRIBERS AND OPIOID TRAINING

Course Director:

  • Michael Lynch, MD  - UPMC Health Plan Quality and Substance Use Disorder Services Senior Medical Director | Director, UPMC Medical Toxicology Telemedicine Bridge Clinic |
    Associate Professor, Division of Medical Toxicology, Department of Emergency Medicine, University of Pittsburgh School of Medicine  

Planning Committee: (alphabetical order)

  • Pam McCormick, PharmD, BCPS, BCEMP - Residency Program Director, Clinical Pharmacist: Emergency Medicine, UPMC
  • Anthony Pizon, MD, FACMT -  Professor of Emergency Medicine, Chief of the Division of Medical Toxicology, University of Pittsburgh School of Medicine |  Attending Emergency Physician & Medical Toxicologist, UPMC | Chief of the Division of Medical Toxicology, University of Pittsburgh School of Medicine | Medical Review Officer, UPMC Urgent Care | Program Director, Fellowship in Medical Toxicology, University of Pittsburgh School of Medicine
  • Kathleen Roth, PA-C - Physician Assistant, Emergency Medicine, UPMC

Topics and Presenters: (in order of presentation)

  • Introduction and Overview:  Michael Lynch, MD - UPMC Health Plan Quality and Substance Use Disorder Services Senior Medical Director | Director, UPMC Medical Toxicology Telemedicine Bridge Clinic | Associate Professor, Division of Medical Toxicology, Department of Emergency Medicine, University of Pittsburgh School of Medicine
  • Overdose Epidemiology, Medetomidine Identification, and Public Health Response, e.g. HAN: Michael Abesamis, MD - Assistant Professor of Emergency Medicine, University of Pittsburgh | Attending Emergency Physician and Medical Toxicologist at UPMC | Director of the UPMC Medical Toxicology Outpatient Clinic. 
  • Structure, PK, Mechanism: Joshua Shulman, MD - Assistant Professor of Emergency Medicine, University of Pittsburgh | Assistant Professor, Department of Community Health Services and Rehabilitation Science, University of Pittsburgh School of Health and Rehabilitation Sciences | Attending Emergency Physician & Medical Toxicologist, UPMC | Medical Director, Pittsburgh Poison Center
  • Acute Toxicity and Management:  Matthew Scanlon, MD - Assistant Professor of Emergency Medicine, University of Pittsburgh School of Medicine | Medical Director of the Division of Hyperbaric Medicine, UPMC | Attending Emergency Physician & Medical Toxicologist, UPMC 
  • Withdrawal and Management including Pathology Role in Connecting Syndrome to Medetomidine:  William Trautman, MD - Assistant Professor of Emergency Medicine, University of Pittsburgh |  Assistant Program Director, Fellowship in Medical Toxicology, University of Pittsburgh School of Medicine | Attending Emergency Physician & Medical Toxicologist, UPMC
  • Summary and Potential Impact:  Michael Lynch, MD - Medical Director, Pittsburgh Poison Center | Medical Director, UPMC Health Plan Substance Use Disorder Services | Assistant Professor, Division of Medical Toxicology, Department of Emergency Medicine | Divisions of Adolescent and Pediatric Emergency Medicine, Department of Pediatrics | University of Pittsburgh School of Medicine 
     

Conflict of Interest Disclosure:
No planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

image
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician (CME)
The University of Pittsburgh designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit[s]™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistant (AAPA)
The University of Pittsburgh has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Nursing (ANCC)
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.

Pharmacy (CPE)
This knowledge-based activity provides 1.0 contact hours of continuing pharmacy education credit.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

DEA Medication Access and Training Expansion (MATE) Act
This training is designed to meet the training requirements for the Medication Access and Training Expansion (MATE) Act of 2023.

Pennsylvania Opioid/Pain Management Credit (physicians only)
This activity has been designated as and qualifies for Opioid/Pain Management Credit. It is the responsibility of the learner to maintain the educational presentation or conference agenda as evidence, if needed for audit purpose

 

 

Available Credit

  • 1.00 AAPA Category I CME
    • 1.00 Opioid Education
  • 1.00 ACPE Pharmacy
    The UPMC Center for Continuing Education in the Health Sciences is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a Provider of continuing pharmacy education.
    • 1.00 Opioid Education
  • 1.00 AMA PRA Category 1 Credit™
    The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
    • 1.00 Opioid Education
  • 1.00 ANCC
    UPMC Provider Unit is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation
    • 1.00 Opioid Education
  • 1.00 Attendance
    • 1.00 Opioid Education
Please login or register to take this course.

PLEASE NOTE: Your NABP and DOB must be in your profile in order to have credits submitted to the ACPE and pharmacy credits awarded.

Choose Register/Complete Course to complete the module.

First time Users: If you have never completed training on this website, please select register in the upper right hand corner of the webpage.

Returning Users: If you have completed training on this website, please log in in the upper right hand corner of the webpage.